Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 406

Similar articles for PubMed (Select 9854048)

1.

Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.

Yang YG, Dey BR, Sergio JJ, Pearson DA, Sykes M.

J Clin Invest. 1998 Dec 15;102(12):2126-35.

2.
3.

IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.

Szebeni J, Wang MG, Pearson DA, Szot GL, Sykes M.

Transplantation. 1994 Dec 27;58(12):1385-93.

PMID:
7809932
4.

Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.

Murphy WJ, Welniak LA, Taub DD, Wiltrout RH, Taylor PA, Vallera DA, Kopf M, Young H, Longo DL, Blazar BR.

J Clin Invest. 1998 Nov 1;102(9):1742-8.

5.
7.

Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation.

Min CK, Maeda Y, Lowler K, Liu C, Clouthier S, Lofthus D, Weisiger E, Ferrara JL, Reddy P.

Blood. 2004 Nov 15;104(10):3393-9. Epub 2004 Jul 27.

9.

Opposing roles of interferon-gamma on CD4+ T cell-mediated graft-versus-host disease: effects of conditioning.

Welniak LA, Blazar BR, Anver MR, Wiltrout RH, Murphy WJ.

Biol Blood Marrow Transplant. 2000;6(6):604-12.

PMID:
11128810
10.
11.

Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.

Blazar BR, Lees CJ, Martin PJ, Noelle RJ, Kwon B, Murphy W, Taylor PA.

J Immunol. 2000 Nov 1;165(9):4901-9.

13.

Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.

Jones MS, Riley R, Hamilton BL, Paupe J, Perez D, Levy RB.

Bone Marrow Transplant. 1994 Nov;14(5):725-35.

PMID:
7889005
15.
16.

Murine graft-versus-host disease in an F1-hybrid model using IFN-gamma gene knockout donors.

Ellison CA, Fischer JM, HayGlass KT, Gartner JG.

J Immunol. 1998 Jul 15;161(2):631-40.

17.

Interleukin-12 inhibits murine graft-versus-host disease.

Sykes M, Szot GL, Nguyen PL, Pearson DA.

Blood. 1995 Sep 15;86(6):2429-38.

18.

Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects.

Reddy P, Teshima T, Hildebrandt G, Williams DL, Liu C, Cooke KR, Ferrara JL.

Blood. 2003 Apr 1;101(7):2877-85. Epub 2002 Nov 14.

19.

Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease.

Blaser BW, Roychowdhury S, Kim DJ, Schwind NR, Bhatt D, Yuan W, Kusewitt DF, Ferketich AK, Caligiuri MA, Guimond M.

Blood. 2005 Jan 15;105(2):894-901. Epub 2004 Sep 16.

20.

IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease.

Ramirez-Montagut T, Chow A, Kochman AA, Smith OM, Suh D, Sindhi H, Lu S, Borsotti C, Grubin J, Patel N, Terwey TH, Kim TD, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MR.

J Immunol. 2007 Aug 1;179(3):1669-80.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk